Clinical Trial Search

Primary: Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population — 50…

Primary: Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations — .4; .25 proportion of…

Primary: 3-year Event-free Survival (EFS) Rate — 66.0 Percentage of Participants — p=0.032

Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients

Primary: Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone — 159.7; 144.6 mg/dl

Primary: Number of Subjects With Treatment-emergent Adverse Events — 2; 1; 1; 0 participants

Primary: Proportion of Participants With Objective Response Rate (ORR) — 5 Participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12) — 96.2 percentage of participants

Primary: Number of Participants Requiring Naloxone — 0 Participants

Primary: Change in Language (Total Standard Score, Range 40 - 160) — 79.62; 79.66; 80.45; 80.59 units on a scale

Primary: Measurement of Sensitivity of DCFBC-PET as Determined by Agreement of PET/CT Detection of Metastatic Prostate Cancer With Conventional Imaging Modality (CIM) — 148; 170…

Primary: Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor — 12.91; 13.49; 12.43; 9.35 percentage of voice signal with tremor — p=0.0216

Primary: To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. — 0; 0; 0; 13 Participants — p==0.0401

Primary: Number of Patients With Dose Limiting Toxicity — 0 Participants

Primary: Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 0; 1 Participants